Splitomicin was used to inhibit SIRT1 in human aortic endothelial cells[2][3]and sirtuins in human breast cancer cells.[5]Mouse leukaemic monocyte macrophage cell line was treated with Splitomicin prior to cholesterol efflux studies.

For R&D use onlynot for drug household or other uses.

Splitomicin is a selective and potent inhibitor of Sir2 (silent information regulator 2) producing an inhibitory effect on neutrophils. Acts as an anti-inflammatory agent.